Lv12
48 积分 2024-07-18 加入
Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma
3小时前
已完结
Les lymphomes de la zone marginale : les différentes entités, leur diagnostic et prise en charge en 2024
1天前
求助中
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial
5天前
已完结
Moving cellular therapies to the front line for Ph+ B cell acute lymphoblastic leukemia
7天前
已完结
A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up
7天前
已完结
Implications of High Tumor Burden on Chimeric Antigen Receptor T-Cell Immunotherapy
11天前
已完结
CAR T-cell therapy for multiple myeloma: state of the art and prospects
11天前
已完结
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial
11天前
已完结
Outcomes of CD19 CAR‐T therapy in central nervous system lymphoma: Insights from a multicentre experience
11天前
已完结
A pilot study of cord blood-derived natural killer cells as maintenance therapy after autologous hematopoietic stem cell transplantation
29天前
已完结
皖公网安备34019202002308
